Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS - Copenhagen Menopause Study
2025-522558-37-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Aug 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AndroForte, Pamorelin, estradiol and Placebo-COD Research Private Ltd in menopause (4 arms), sponsored by Capital Region of Denmark. Primary endpoint: Change in bone remodeling. Planned start Aug 2025; status: authorised.
02
Drugs
AndroFortePamorelinestradiolPlacebo-COD Research Private Ltd
03
Conditions
menopause
Beyond the preview
Go deeper on 2025-522558-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522558-37-00.